Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC

Author:

Kubicek Pierre,Cesne Axel Le,Lervat Cyril,Toulmonde Maud,Chevreau Christine,Duffaud Florence,Le Nail Louis-Romée,Morelle Magali,Gaspar Nathalie,Vérité Cécile,Castex Marie-Pierre,Penel Nicolas,Saada Esma,Causeret Sylvain,Bertucci François,Perrin Christophe,Bompas Emmanuelle,Orbach Daniel,Laurence Valérie,Piperno-Neumann Sophie,Anract Philippe,Rios Maria,Gentet Jean-Claude,Mascard Éric,Pannier Stéphanie,Blouin Pascale,Carrère Sébastien,Chaigneau Loïc,Soibinet-Oudot Pauline,Corradini Nadège,Boudou-Rouquette Pascaline,Ruzic Jean-Christophe,Lebrun-Ly Valérie,Dubray-Longeras Pascale,Varatharajah Sharmini,Lebbe Céleste,Ropars Mickaël,Kurtz Jean-Emmanuel,Guillemet Cécile,Lotz Jean-Pierre,Berchoud Juliane,Cherrier Grégory,Ducimetière Françoise,Chemin Claire,Italiano Antoine,Honoré Charles,Desandes Emmanuel,Blay Jean-Yves,Gouin François,Marec-Bérard Perrine

Abstract

Abstract Background The initial management of patients with sarcoma is a critical issue. We used the nationwide French National Cancer Institute-funded prospective sarcoma database NETSARC to report the management and oncologic outcomes in adolescents and young adults (AYAs) patients with sarcoma at the national level. Patients and methods NETSARC database gathers regularly monitored and updated data from patients with sarcoma. NETSARC was queried for patients (15–30 years) with sarcoma diagnosed from 2010 to 2017 for whom tumor resection had been performed. We reported management, locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS) in AYA treated in French reference sarcoma centers (RSC) and outside RSC (non-RSC) and conducted multivariable survival analyses adjusted for classical prognostic factors. Results Among 3,227 patients aged 15–30 years with sarcoma diagnosed between 2010 and 2017, the study included 2,227 patients with surgery data available, among whom 1,290 AYAs had been operated in RSC, and 937 AYAs in non-RSC. Significant differences in compliance to guidelines were observed including pre-treatment biopsy (RSC: 85.9%; non-RSC 48.1%), pre-treatment imaging (RSC: 86.8%; non-RSC: 56.5%) and R0 margins (RSC 57.6%; non-RSC: 20.2%) (p < 0.001). 3y-OS rates were 81.1% (95%CI 78.3–83.6) in AYA in RSC and 82.7% (95%CI 79.4–85.5) in AYA in non-RSC, respectively. Whereas no significant differences in OS was observed in AYAs treated in RSC and in non-RSC, LRFS and PFS were improved in AYAs treated in RSC compared to AYAs treated in non-RSC (Hazard Ratios (HR): 0.58 and 0.83, respectively). Conclusions This study highlights the importance for AYA patients with sarcoma to be managed in national sarcoma reference centers involving multidisciplinary medical teams with paediatric and adult oncologists.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Reference36 articles.

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3